BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shiha GE, Abu-elsaad NM, Zalata KR, Ibrahim TM. Tracking anti-fibrotic pathways of nilotinib and imatinib in experimentally induced liver fibrosis: An insight. Clin Exp Pharmacol Physiol 2014;41:788-97. [DOI: 10.1111/1440-1681.12286] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Ying HZ, Chen Q, Zhang WY, Zhang HH, Ma Y, Zhang SZ, Fang J, Yu CH. PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics (Review). Mol Med Rep. 2017;16:7879-7889. [PMID: 28983598 DOI: 10.3892/mmr.2017.7641] [Cited by in Crossref: 66] [Cited by in F6Publishing: 58] [Article Influence: 16.5] [Reference Citation Analysis]
2 Ashry NA, Abdеlaziz RR, Suddеk GM. The potential effect of imatinib against hypercholesterolemia induced atherosclerosis, endothelial dysfunction and hepatic injury in rabbits. Life Sci 2020;243:117275. [PMID: 31926242 DOI: 10.1016/j.lfs.2020.117275] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
3 Mohammadalipour A, Karimi J, Khodadadi I, Solgi G, Hashemnia M, Sheikh N, Bahabadi M. Dasatinib prevent hepatic fibrosis induced by carbon tetrachloride (CCl 4 ) via anti-inflammatory and antioxidant mechanism. Immunopharmacology and Immunotoxicology 2017;39:19-27. [DOI: 10.1080/08923973.2016.1263860] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
4 Mazhari S, Gitiara A, Baghaei K, Hatami B, Rad RE, Asadirad A, Joharchi K, Tokhanbigli S, Hashemi SM, Łos MJ, Aghdaei HA, Zali MR, Ghavami S. Therapeutic potential of bone marrow-derived mesenchymal stem cells and imatinib in a rat model of liver fibrosis. Eur J Pharmacol 2020;882:173263. [PMID: 32535098 DOI: 10.1016/j.ejphar.2020.173263] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
5 Barghi M, Ashrafi M, Aminlari M, Namazi F, Nazifi S. The protective effect of Zataria multiflora Boiss essential oil on CCl4 induced liver fibrosis in rats. Drug Chem Toxicol 2021;44:229-37. [PMID: 30746963 DOI: 10.1080/01480545.2019.1571502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Nabil A, Uto K, Zahran F, Soliman R, Hassan AA, Elshemy MM, Ali IS, Ebara M, Shiha G. The Potential Safe Antifibrotic Effect of Stem Cell Conditioned Medium and Nilotinib Combined Therapy by Selective Elimination of Rat Activated HSCs. Biomed Res Int 2021;2021:6678913. [PMID: 33855079 DOI: 10.1155/2021/6678913] [Reference Citation Analysis]
7 Weiskirchen R. Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step. Front Pharmacol. 2015;6:303. [PMID: 26779021 DOI: 10.3389/fphar.2015.00303] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
8 Burke MJ, Walmsley R, Munsey TS, Smith AJ. Receptor tyrosine kinase inhibitors cause dysfunction in adult rat cardiac fibroblasts in vitro. Toxicology in Vitro 2019;58:178-86. [DOI: 10.1016/j.tiv.2019.03.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
9 Borkham-Kamphorst E, Weiskirchen R. The PDGF system and its antagonists in liver fibrosis. Cytokine Growth Factor Rev. 2016;28:53-61. [PMID: 26547628 DOI: 10.1016/j.cytogfr.2015.10.002] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 11.8] [Reference Citation Analysis]
10 Elshal M, Abu-elsaad N, El-karef A, Ibrahim TM. The multi-kinase inhibitor pazopanib targets hepatic stellate cell activation and apoptosis alleviating progression of liver fibrosis. Naunyn-Schmiedeberg's Arch Pharmacol 2015;388:1293-304. [DOI: 10.1007/s00210-015-1157-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
11 Fan QQ, Zhang CL, Qiao JB, Cui PF, Xing L, Oh YK, Jiang HL. Extracellular matrix-penetrating nanodrill micelles for liver fibrosis therapy. Biomaterials 2020;230:119616. [PMID: 31837823 DOI: 10.1016/j.biomaterials.2019.119616] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
12 Qu K, Huang Z, Lin T, Liu S, Chang H, Yan Z, Zhang H, Liu C. New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials. Front Pharmacol. 2016;6:300. [PMID: 26834633 DOI: 10.3389/fphar.2015.00300] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
13 Shiha G, Nabil A, Lotfy A, Soliman R, Hassan AA, Ali IS, Gad DF, Zahran F. Antifibrotic Effect of Combination of Nilotinib and Stem Cell-Conditioned Media on CCl4-Induced Liver Fibrosis. Stem Cells Int 2020;2020:6574010. [PMID: 32089708 DOI: 10.1155/2020/6574010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
14 Qu K, Liu T, Lin T, Zhang X, Cui R, Liu S, Meng F, Zhang J, Tai M, Wan Y, Liu C. Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis? Oncotarget 2016;7:67650-60. [PMID: 27588502 DOI: 10.18632/oncotarget.11767] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
15 Kang HS, Rhee CK, Lee HY, Yoon HK, Kwon SS, Lee SY. Different anti-remodeling effect of nilotinib and fluticasone in a chronic asthma model. Korean J Intern Med 2016;31:1150-8. [PMID: 27764539 DOI: 10.3904/kjim.2015.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
16 Papadopoulos N, Lennartsson J. The PDGF/PDGFR pathway as a drug target. Molecular Aspects of Medicine 2018;62:75-88. [DOI: 10.1016/j.mam.2017.11.007] [Cited by in Crossref: 75] [Cited by in F6Publishing: 78] [Article Influence: 25.0] [Reference Citation Analysis]
17 Beketova TV, Volkov MY, Naryshkin EA, Novoselova TM, Nasonov EL. Imatinib mesylate use in refractory eosinophilic granulomatosis with polyangiitis: a literature review and a case report. Clin Rheumatol 2018;37:1729-35. [DOI: 10.1007/s10067-018-4018-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
18 Karimi J, Mohammadalipour A, Sheikh N, Khodadadi I, Hashemnia M, Goudarzi F, Khanjarsim V, Solgi G, Hajilooi M, Bahabadi M, Kheiripour N, Hedayatyanfard K. Protective effects of combined Losartan and Nilotinib on carbon tetrachloride (CCl4)-induced liver fibrosis in rats. Drug Chem Toxicol 2020;43:468-78. [PMID: 30207194 DOI: 10.1080/01480545.2018.1504960] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
19 Mohammadalipour A, Hashemnia M, Goudarzi F, Ravan AP. Increasing the effectiveness of tyrosine kinase inhibitor (TKI) in combination with a statin in reducing liver fibrosis. Clin Exp Pharmacol Physiol 2019;46:1183-93. [PMID: 31396972 DOI: 10.1111/1440-1681.13157] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
20 El-Agamy DS. Nilotinib attenuates endothelial dysfunction and liver damage in high-cholesterol-fed rabbits. Hum Exp Toxicol 2017;36:1131-45. [PMID: 27941169 DOI: 10.1177/0960327116681649] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
21 Ustun C, Randall N, Podgaetz E, Amin K, Dincer HE. Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor. Thorax 2015;70:701-4. [PMID: 25935168 DOI: 10.1136/thoraxjnl-2015-206841] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
22 Khanjarsim V, Karimi J, Khodadadi I, Mohammadalipour A, Goodarzi MT, Solgi G, Hashemnia M. Ameliorative Effects of Nilotinib on CCl4 Induced Liver Fibrosis Via Attenuation of RAGE/HMGB1 Gene Expression and Oxidative Stress in Rat. Chonnam Med J 2017;53:118-26. [PMID: 28584790 DOI: 10.4068/cmj.2017.53.2.118] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
23 Tan Z, Sun H, Xue T, Gan C, Liu H, Xie Y, Yao Y, Ye T. Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy. Front Cell Dev Biol 2021;9:730176. [PMID: 34621747 DOI: 10.3389/fcell.2021.730176] [Reference Citation Analysis]
24 Haguet H, Douxfils J, Chatelain C, Graux C, Mullier F, Dogné JM. BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis? TH Open 2018;2:e68-88. [PMID: 31249931 DOI: 10.1055/s-0038-1624566] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
25 Abu-Elsaad NM, Elkashef WF. Modified citrus pectin stops progression of liver fibrosis by inhibiting galectin-3 and inducing apoptosis of stellate cells. Can J Physiol Pharmacol. 2016;94:554-562. [PMID: 27010252 DOI: 10.1139/cjpp-2015-0284] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]